Generic Name and Formulations:
Polyethylene glycol 3350 420g, sodium bicarbonate 5.72g, sodium chloride 11.2g, potassium chloride 1.4g; per 4L of soln; pwd for reconstitution; cherry, lemon-lime, orange, or pineapple flavor.
Braintree Laboratories, Inc.
Indications for NuLYTELY:
Bowel cleansing before colonoscopy.
May consume water or clear liquids during and after completion of bowel prep up until 2hrs before procedure. Drink 240mL orally every 10 mins or 20–30mL/min by NG tube until rectal effluent is clear or 4L consumed. May interrupt if severe GI disturbances occur.
<6 months: not recommended. ≥6 months: May consume water or clear liquids during and after completion of bowel prep up until 2hrs before procedure. Drink 25mL/kg per hour orally or by NG tube until rectal effluent is clear or 4L consumed. May interrupt if severe GI disturbances occur.
GI obstruction. Bowel perforation. Gastric retention. Ileus. Toxic colitis or megacolon.
Not for direct ingestion. Correct fluid/electrolyte abnormalities before use. History of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy: increased risk of arrhythmias; consider ECGs at pre-dose and post-colonoscopy. History or risk of seizures. Renal impairment; monitor baseline and post-colonoscopy electrolytes, creatinine, BUN. Inflammatory bowel disease. Rule out suspected GI obstruction/perforation before administering. Severe ulcerative colitis. Impaired gag reflex. Semi- or unconscious patients. Risk of regurgitation or aspiration. Monitor young children (<2yrs) for hypoglycemia. Maintain adequate hydration. Pregnancy (Cat.C). Nursing mothers.
Caution with drugs that increase risk of fluid/electrolyte abnormalities, arrhythmias or QT prolongation. Drugs that may lower the seizure threshold (eg, tricyclic antidepressants), alcohol or benzodiazepine withdrawal, known or suspected hyponatremia: may increase risk of seizures. Concomitant diuretics, ACE inhibitors, ARBs, NSAIDs; may affect renal function. Avoid concomitant stimulant laxatives (eg, bisacodyl, sodium picosulfate). Oral drugs administered within 1hr of start of Nulytely may not be absorbed.
Nausea, abdominal fullness and bloating, cramps, vomiting, anal irritation; seizures, arrhythmias, mucosal ulcerations and ischemic colitis. Children: also dehydration or hypokalemia.
Disposable jug (4L)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC